> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Formycon Wins Stelara Interchangeability for Biosimilar
- URL: https://www.fdaweb.com/formycon-wins-stelara-interchangeability-for-biosimilar/
- Published: 2025-05-19T12:00:00.000Z
- Updated: 2026-09-14T15:12:12.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5159208

FDA has designated Formycon’s FYB202/Otulfi (ustekinumab-aauz) as an interchangeable biosimilar to Janssen’s reference biologic Stelara (ustekinumab) for treating psoriatic arthritis and plaque psoriasis, as well as Crohn’s disease, and ulcerative colitis. Ustekinumab is a human monoclonal antibody that selectively targets the p40 protein, a component common to both interleukin (IL)-12 and IL-23 cytokines, which play crucial roles in treating immune-mediated diseases like psoriasis and psoriatic arthritis, and inflammatory diseases like Crohn’s disease and ulcerative colitis, the company says.

FYB202/Otulfi was approved 9/2024 for treating the same conditions as Stelara. The approval and interchangeability designation are “based on a thorough evaluation of a comprehensive data package including analytical, pre-clinical, clinical and manufacturing data,” the company says.